ASMB vs FDMT: fair value comparison
Assembly Biosciences, Inc. and 4D Molecular Therapeutics, Inc. · Updated 2026-10-19
ASMB has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. FDMT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, ASMB currently ranks higher by quality score.
| ASMB | FDMT | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $20.09 | $12.14 |
| 12-month range | $20.09–$38.50 | $7.19–$16.76 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #163 of 301 Healthcare | #164 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: ASMB fair value analysis · FDMT fair value analysis